Where you areHER2-positive breast cancer

Back to the HER2-positive breast cancer hub →29 centres

Cases by country, the UK and NHS pathway and other country lenses, and the expert centres with trials on record.

Where you are

top

Every country →Coverage by country →

Cases by country

Cases by country · GLOBOCAN 2022

All countries →

Site: Breast (all subtypes) (shared total; subtype split not reported). World: 2,296,840 new cases a year.

#	Country	New cases	Incidence ASR
1	China	357,161	33.0
2	United States of America	274,375	95.9
3	India	192,020	26.6
4	Brazil	94,728	63.1
5	Japan	91,916	74.4
6	Russian Federation	78,839	57.7
7	Germany	74,016	77.0
8	Indonesia	66,271	41.8
9	France (metropolitan)	65,659	105.4
10	United Kingdom	58,756	94.0

GLOBOCAN reports breast cancer as one site. HER2+ disease is roughly 15-20% of cases; the figures shown are for all breast cancer.

Show deaths by countryGLOBOCAN's estimated deaths for the same countries, for readers who want them.

Country-level death counts mix every stage, subtype and year of diagnosis, and reflect access to screening and treatment as much as the disease. Survival differs by stage, subtype and year; the cancer page above leads with what can be done.

#	Country	New cases	Deaths
1	China	357,161	74,986
2	United States of America	274,375	42,900
3	India	192,020	98,337
4	Brazil	94,728	22,189
5	Japan	91,916	17,638
6	Russian Federation	78,839	22,115
7	Germany	74,016	20,601
8	Indonesia	66,271	22,598
9	France (metropolitan)	65,659	14,739
10	United Kingdom	58,756	12,122

World: 2,296,840 new cases and 666,103 deaths a year (GLOBOCAN 2022).

Expert centres

Where the expertise is

Expert centres

87 centres in 24 countries · 9 with a trial for this cancer on record · second-opinion finder →

Choose a region from the globe in the header to mark centres near you.

87 centres


Gustave Roussy Villejuif · cancer center Programme: Breast ADC trials	France	none recorded	0	1,862	31,707	ZAP-X gyroscopic radiosurgery Stereotactic radiosurgery (Gamma Knife, CyberKnife, linac SRS)	#6
IEO (European Institute of Oncology) Milan · cancer center Programme: Breast surgery, Breast medical oncology	Italy	none recorded	0	1,252	21,584	Sentinel lymph node biopsy	#11
National Cancer Center Hospital Tokyo · government	Japan	none recorded	0	1,599	21,937	none recorded	#13
Vall d'Hebron University Hospital / VHIO Barcelona · cancer center Programme: Breast ADC trials (Cortés)	Spain	none recorded	2	967	23,548	none recorded	#28
Stanford Health Care / Stanford Cancer Institute Stanford · university	United States	NCI comprehensive	0	3,016	50,896	CAR-T cell therapy SBRT / SABR (stereotactic radiotherapy)CyberKnife robotic radiosurgery Stereotactic radiosurgery (Gamma Knife, CyberKnife, linac SRS)+1	#30
Cancer Hospital, Chinese Academy of Medical Sciences Beijing · cancer center	China	none recorded	0	365	3,800	none recorded	#50
The Institute of Cancer Research London · research institute	United Kingdom	none recorded	2	637	10,594	none recorded	-
NSABP Foundation Pittsburgh, PA · consortium Programme: B-04 / B-06 (breast conservation)	United States	none recorded	2	58	1,268	Sentinel lymph node biopsy Endocrine therapy (SERMs, AIs, SERDs)Chemoprevention & risk-reducing surgery	-
Georgetown Lombardi Comprehensive Cancer Center Washington, DC · cancer center Programme: Breast cancer (CLEOPATRA)	United States	NCI comprehensive	1	100	2,434	Monoclonal antibodies Endocrine therapy (SERMs, AIs, SERDs)Proton therapy Proton therapy machines: cyclotrons, synchrotrons and single-room systems +2	-
NRG Oncology Philadelphia, PA · consortium	United States	none recorded	1	87	2,130	none recorded	-
Canadian Cancer Trials Group (CCTG) Kingston, ON · consortium Programme: Breast endocrine therapy trials (MA series)	Canada	none recorded	1	32	323	Exercise & lifestyle oncology SBRT / SABR (stereotactic radiotherapy)	-
Breast Cancer Trials Newcastle, NSW · consortium	Australia	none recorded	1	10	554	Endocrine therapy (SERMs, AIs, SERDs)PARP inhibitors	-
Cancer Research UK London · consortium	United Kingdom	none recorded	1	not matched	-	none recorded	-
EORTC Brussels · consortium	Belgium	none recorded	1	not matched	-	none recorded	-
UCLA Jonsson Comprehensive Cancer Center Los Angeles · cancer center	United States	NCI comprehensive	0	2,039	33,523	PSMA PET MR-guided adaptive radiotherapy	-

(showing the first 15)

These are the things we can measure; they are not a ranking of quality. Each column is a field on the institution record or a count over what OnCo has linked; a centre that treats many patients with HER2-positive breast cancer but is thinly recorded here will look small.

Not known: OnCo holds no case-volume or outcome figures for centres, so none are shown. Where a national audit or registry publishes them, the centre's page links to it. Default order: Newsweek rank, then trials for this cancer, then research output.

Seeking a second opinion: ask your oncologist for a referral to a high-volume centre; most accept records and pathology by mail or telehealth. In the US, use the NCI's Find a Cancer Center tool or the nonprofit Cancer Commons, which navigates options for advanced cancers at no cost. The second-opinion finder explains how referral works in your country.

Model panel1 model

Machine commentary by named AI models on a date, not clinical review. Claims are tied to the record's own sources; check them before relying on anything here.

FableAnthropic · v5.12026-09-17low confidence

The record's core narrative is sound and consistent with its cited overview: HER2 amplification as an adverse marker, trastuzumab in 1998, adjuvant dual blockade, response-adapted post-neoadjuvant therapy and de-escalation for small node-negative tumours. Its weaknesses are sourcing and internal consistency. Much of the standard of care now rests on 2025 and 2026 approvals (DESTINY-Breast09, DESTINY-Breast05, DESTINY-Breast11, PATINA) and on figures such as PFS 40.7 months, iDFS HR 0.47, pCR 67% and 400,000 cases a year that none of the three listed sources can be shown to contain, and the record itself admits the NCCN guideline is 'pending update' for T-DXd in one setting while claiming category 1 for it in another. ESMO-MCBS grades are attached to an NCCN URL. The history, biomarkers and state-of-the-art lists contain duplicated entries, the 'Stage I' setting label mixes stage I and IIA tumours, and the inclusion of HER2-mutant, non-amplified disease as a subtype contradicts the record's own IHC 3+/ISH-amplified definition.

Right 2Disputed 1Unclear 4Show verdicts

Right
HER2-positive breast cancer (15-20% of cases; HER2 IHC 3+ or ISH-amplified) was the most aggressive subtype until trastuzumab (1998) made it one of the most treatable.
The definition, prevalence range and the 1998 trastuzumab turning point are consistent with the encyclopaedic overview the record cites. Two internal points weaken presentation: the history section carries the Slamon 1987, trastuzumab 1998, T-DM1 2013, DESTINY-Breast03 2021 and 2026 entries twice each, and the Slamon note quotes 25-30% amplification while the headline says 15-20%, a gap the record does not explain (older assays versus current ASCO/CAP criteria).
Wikipedia
Right
Stage I (≤2-3 cm, node-negative): surgery then weekly paclitaxel × 12 + trastuzumab × 1 year (APT); T-DM1 × 17 cycles is an alternative (ATEMPT).
De-escalated paclitaxel-trastuzumab for small node-negative HER2-positive tumours is the approach the cited NCCN guideline covers, and the NCCN 2A label is plausible. The setting label is loose: a node-negative tumour of 2-3 cm is stage IIA, not stage I, so '≤2-3 cm' and 'Stage I' do not describe the same group.
Guideline (Stage I (≤2-3 cm, node-negative))
Unclear
T-DXd (DESTINY-Breast05, iDFS HR 0.47 vs T-DM1; approved 2026) replacing T-DM1 (KATHERINE)
The record's own guideline field for this setting reads 'NCCN 1 (T-DM1); T-DXd pending update', so the cited guideline does not yet back T-DXd here. The Stage II-III neoadjuvant entry claims NCCN category 1 for 'T-DXd × 4 → THP' without the same caveat, which is internally inconsistent. Neither listed source can be shown to cover the 2026 approvals.
Guideline (Stage I (≤2-3 cm, node-negative))
Unclear
esmoMcbs: A (KATHERINE); A (HERA); C (NeoSphere, APHINITY)
ESMO-MCBS grades are attached to a guideline object whose only URL is the NCCN early-stage article. NCCN does not issue ESMO-MCBS scores, and no ESMO source is listed, so the grades (here and the '4' scores in the metastatic settings) cannot be checked against the record's sources.
NCCN Guidelines: Breast Cancer (Early stage)
Disputed
HER2-mutant (activating mutations without amplification; T-DXd tumour-agnostic, HER2 TKIs; more common in lobular and HER2-low)
The record defines HER2-positive disease as IHC 3+ or ISH-amplified, and this subtype is described as lacking amplification and being commoner in HER2-low tumours. By the record's own definition it is not a subtype of HER2-positive breast cancer; it belongs in a HER2-mutant or HER2-low record.
Wikipedia
Unclear
T-DXd + pertuzumab first line (DESTINY-Breast09, PFS 40.7 months; approved 2025) ... palbociclib maintenance (PATINA, approved 2026)
The record's metastatic standard of care rests on approvals dated 2025 and 2026 and on a PFS figure and NCCN 'category 1, preferred' status that none of the three listed sources is shown to contain. Linked OnCo records repeat the same claims but are not independent sources. Primary regulatory or trial references should be attached.
Guideline (Stage I (≤2-3 cm, node-negative))
Unclear
Brain metastases, which develop in up to half of patients, are now treatable systemically with tucatinib (HER2CLIMB) and T-DXd (DESTINY-Breast12).
The 'up to half' figure is stated consistently in the summary and open problems and matches the linked term record, but none of the listed sources is shown to give this incidence, nor the DESTINY-Breast12 intracranial response rate of 72% quoted in the brain metastases setting. The tucatinib triplet's role in brain metastases is well established and plausibly in the NCCN guideline cited.
Wikipedia

Human reviews sit on top of the panel. Add a clinical review or see the review queue.

ProvenanceLast edited 2026-09-18 · Jude Gomila · Link cancer subtypes to their siblings and name parents i… · diff · file · history

Wikipedia

HER2-positive breast cancer

Sources & links

Wikipedia

Where you areHER2-positive breast cancer

Back to the HER2-positive breast cancer hub →29 centres

Cases by country, the UK and NHS pathway and other country lenses, and the expert centres with trials on record.

Where you are

top

Every country →Coverage by country →

Cases by country

Cases by country · GLOBOCAN 2022

All countries →

Site: Breast (all subtypes) (shared total; subtype split not reported). World: 2,296,840 new cases a year.

#	Country	New cases	Incidence ASR
1	China	357,161	33.0
2	United States of America	274,375	95.9
3	India	192,020	26.6
4	Brazil	94,728	63.1
5	Japan	91,916	74.4
6	Russian Federation	78,839	57.7
7	Germany	74,016	77.0
8	Indonesia	66,271	41.8
9	France (metropolitan)	65,659	105.4
10	United Kingdom	58,756	94.0

GLOBOCAN reports breast cancer as one site. HER2+ disease is roughly 15-20% of cases; the figures shown are for all breast cancer.

Show deaths by countryGLOBOCAN's estimated deaths for the same countries, for readers who want them.

#	Country	New cases	Deaths
1	China	357,161	74,986
2	United States of America	274,375	42,900
3	India	192,020	98,337
4	Brazil	94,728	22,189
5	Japan	91,916	17,638
6	Russian Federation	78,839	22,115
7	Germany	74,016	20,601
8	Indonesia	66,271	22,598
9	France (metropolitan)	65,659	14,739
10	United Kingdom	58,756	12,122

World: 2,296,840 new cases and 666,103 deaths a year (GLOBOCAN 2022).

Expert centres

Where the expertise is

Expert centres

87 centres in 24 countries · 9 with a trial for this cancer on record · second-opinion finder →

Choose a region from the globe in the header to mark centres near you.

87 centres


Gustave Roussy Villejuif · cancer center Programme: Breast ADC trials	France	none recorded	0	1,862	31,707	ZAP-X gyroscopic radiosurgery Stereotactic radiosurgery (Gamma Knife, CyberKnife, linac SRS)	#6
IEO (European Institute of Oncology) Milan · cancer center Programme: Breast surgery, Breast medical oncology	Italy	none recorded	0	1,252	21,584	Sentinel lymph node biopsy	#11
National Cancer Center Hospital Tokyo · government	Japan	none recorded	0	1,599	21,937	none recorded	#13
Vall d'Hebron University Hospital / VHIO Barcelona · cancer center Programme: Breast ADC trials (Cortés)	Spain	none recorded	2	967	23,548	none recorded	#28
Stanford Health Care / Stanford Cancer Institute Stanford · university	United States	NCI comprehensive	0	3,016	50,896	CAR-T cell therapy SBRT / SABR (stereotactic radiotherapy)CyberKnife robotic radiosurgery Stereotactic radiosurgery (Gamma Knife, CyberKnife, linac SRS)+1	#30
Cancer Hospital, Chinese Academy of Medical Sciences Beijing · cancer center	China	none recorded	0	365	3,800	none recorded	#50
The Institute of Cancer Research London · research institute	United Kingdom	none recorded	2	637	10,594	none recorded	-
NSABP Foundation Pittsburgh, PA · consortium Programme: B-04 / B-06 (breast conservation)	United States	none recorded	2	58	1,268	Sentinel lymph node biopsy Endocrine therapy (SERMs, AIs, SERDs)Chemoprevention & risk-reducing surgery	-
Georgetown Lombardi Comprehensive Cancer Center Washington, DC · cancer center Programme: Breast cancer (CLEOPATRA)	United States	NCI comprehensive	1	100	2,434	Monoclonal antibodies Endocrine therapy (SERMs, AIs, SERDs)Proton therapy Proton therapy machines: cyclotrons, synchrotrons and single-room systems +2	-
NRG Oncology Philadelphia, PA · consortium	United States	none recorded	1	87	2,130	none recorded	-
Canadian Cancer Trials Group (CCTG) Kingston, ON · consortium Programme: Breast endocrine therapy trials (MA series)	Canada	none recorded	1	32	323	Exercise & lifestyle oncology SBRT / SABR (stereotactic radiotherapy)	-
Breast Cancer Trials Newcastle, NSW · consortium	Australia	none recorded	1	10	554	Endocrine therapy (SERMs, AIs, SERDs)PARP inhibitors	-
Cancer Research UK London · consortium	United Kingdom	none recorded	1	not matched	-	none recorded	-
EORTC Brussels · consortium	Belgium	none recorded	1	not matched	-	none recorded	-
UCLA Jonsson Comprehensive Cancer Center Los Angeles · cancer center	United States	NCI comprehensive	0	2,039	33,523	PSMA PET MR-guided adaptive radiotherapy	-

(showing the first 15)

Model panel1 model

Machine commentary by named AI models on a date, not clinical review. Claims are tied to the record's own sources; check them before relying on anything here.

FableAnthropic · v5.12026-09-17low confidence

Right 2Disputed 1Unclear 4Show verdicts

Right
HER2-positive breast cancer (15-20% of cases; HER2 IHC 3+ or ISH-amplified) was the most aggressive subtype until trastuzumab (1998) made it one of the most treatable.
The definition, prevalence range and the 1998 trastuzumab turning point are consistent with the encyclopaedic overview the record cites. Two internal points weaken presentation: the history section carries the Slamon 1987, trastuzumab 1998, T-DM1 2013, DESTINY-Breast03 2021 and 2026 entries twice each, and the Slamon note quotes 25-30% amplification while the headline says 15-20%, a gap the record does not explain (older assays versus current ASCO/CAP criteria).
Wikipedia
Right
Stage I (≤2-3 cm, node-negative): surgery then weekly paclitaxel × 12 + trastuzumab × 1 year (APT); T-DM1 × 17 cycles is an alternative (ATEMPT).
De-escalated paclitaxel-trastuzumab for small node-negative HER2-positive tumours is the approach the cited NCCN guideline covers, and the NCCN 2A label is plausible. The setting label is loose: a node-negative tumour of 2-3 cm is stage IIA, not stage I, so '≤2-3 cm' and 'Stage I' do not describe the same group.
Guideline (Stage I (≤2-3 cm, node-negative))
Unclear
T-DXd (DESTINY-Breast05, iDFS HR 0.47 vs T-DM1; approved 2026) replacing T-DM1 (KATHERINE)
The record's own guideline field for this setting reads 'NCCN 1 (T-DM1); T-DXd pending update', so the cited guideline does not yet back T-DXd here. The Stage II-III neoadjuvant entry claims NCCN category 1 for 'T-DXd × 4 → THP' without the same caveat, which is internally inconsistent. Neither listed source can be shown to cover the 2026 approvals.
Guideline (Stage I (≤2-3 cm, node-negative))
Unclear
esmoMcbs: A (KATHERINE); A (HERA); C (NeoSphere, APHINITY)
ESMO-MCBS grades are attached to a guideline object whose only URL is the NCCN early-stage article. NCCN does not issue ESMO-MCBS scores, and no ESMO source is listed, so the grades (here and the '4' scores in the metastatic settings) cannot be checked against the record's sources.
NCCN Guidelines: Breast Cancer (Early stage)
Disputed
HER2-mutant (activating mutations without amplification; T-DXd tumour-agnostic, HER2 TKIs; more common in lobular and HER2-low)
The record defines HER2-positive disease as IHC 3+ or ISH-amplified, and this subtype is described as lacking amplification and being commoner in HER2-low tumours. By the record's own definition it is not a subtype of HER2-positive breast cancer; it belongs in a HER2-mutant or HER2-low record.
Wikipedia
Unclear
T-DXd + pertuzumab first line (DESTINY-Breast09, PFS 40.7 months; approved 2025) ... palbociclib maintenance (PATINA, approved 2026)
The record's metastatic standard of care rests on approvals dated 2025 and 2026 and on a PFS figure and NCCN 'category 1, preferred' status that none of the three listed sources is shown to contain. Linked OnCo records repeat the same claims but are not independent sources. Primary regulatory or trial references should be attached.
Guideline (Stage I (≤2-3 cm, node-negative))
Unclear
Brain metastases, which develop in up to half of patients, are now treatable systemically with tucatinib (HER2CLIMB) and T-DXd (DESTINY-Breast12).
The 'up to half' figure is stated consistently in the summary and open problems and matches the linked term record, but none of the listed sources is shown to give this incidence, nor the DESTINY-Breast12 intracranial response rate of 72% quoted in the brain metastases setting. The tucatinib triplet's role in brain metastases is well established and plausibly in the NCCN guideline cited.
Wikipedia

Human reviews sit on top of the panel. Add a clinical review or see the review queue.

ProvenanceLast edited 2026-09-18 · Jude Gomila · Link cancer subtypes to their siblings and name parents i… · diff · file · history

Wikipedia

HER2-positive breast cancer

Sources & links

Wikipedia